Havana, Cuba

Lourdes Hernández De La Rosa


Average Co-Inventor Count = 16.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Lourdes Hernández De La Rosa and Her Contribution to Cancer Treatment

Introduction

Lourdes Hernández De La Rosa, an accomplished inventor based in Havana, Cuba, has made significant strides in the field of biomedical innovation. With a focus on immunotherapy, her patent for a pharmaceutical composition shows promise in the fight against cancer, particularly by targeting myeloid-derived suppressor cells.

Latest Patents

Lourdes holds a notable patent titled "Ganglioside GM3-containing nanoparticles as immunomodulators." This innovative invention describes a pharmaceutical composition that features conjugates of membrane vesicles and GM3 ganglioside. The composition is characterized by its advantageous properties, including a specific size and surface charge that enhance its efficacy as an immunomodulator. The patent outlines the potential of this composition to significantly reduce the population of myeloid-derived suppressor cells, thereby improving the lymphocyte response and survival rates of patients suffering from tumors.

Career Highlights

Hernández De La Rosa is currently associated with the Centro de Inmunología Molecular, a prominent research institution known for its contributions to immunology. Her work is pivotal in advancing targeted cancer treatments and reflects her dedication to enhancing patient outcomes through innovative pharmaceutical solutions.

Collaborations

Lourdes collaborates with notable colleagues including Circe Mesa Pardillo and Liliana Oliver Ríos. Together, they contribute to various research initiatives that further improve therapeutic approaches in cancer treatment. These collaborations enable a dynamic exchange of ideas and expertise, strengthening the impact of their work in the field.

Conclusion

Lourdes Hernández De La Rosa exemplifies the spirit of innovation in the biomedical sector. Her patent on GM3-containing nanoparticles demonstrates the potential to revolutionize cancer treatment by redefining how we approach the management of myeloid-derived suppressor cells. As she continues her research and collaborations, the implications of her work may lead to significant advancements in cancer therapy, making a lasting difference in the lives of many patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…